Early interim PET scan in Hodgkin lymphoma: Where do we stand?

Leukemia and Lymphoma

Volumn 49, Issue 4, 2008, Pages 659-662

  Gallamini, Andrea ^a   Hutchings, Martin ^b   Avigdor, Abraham ^c   Polliack, Aaron ^d  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b Mental Health Services CPH   (Denmark)

^c SHEBA MEDICAL CENTER   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

ABVD; BEACOPP; Interim; Lymphoma; PET; Prognosis

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HODGKIN DISEASE; HUMAN; INFLAMMATORY CELL; MACROPHAGE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; STANDARD;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 42049087919     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801888704     Document Type: Conference Paper

References (22)

1. Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottagy, F. M., Dietlein, M. and Guernazi, A. (2007) Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol, 25, pp. 571-578.
2. Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L. and Horning, S. J. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol, 25, pp. 579-586.
3. Torizuka, T., Nakamura, F., Kanno, T., Futatsubashi, M., Yoshikawa, E. and Okada, H. (2004) Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging, 31, pp. 22-28.
4. Hutchings, M., Loft, A., Hansen, M., Pedersen, L Moller, Buhl, T. and Jurlander, J. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, pp. 52-59.
5. Gallamini, A., Rigacci, L., Merli, F., Nassi, L., Bosi, A. and Capodanno, I. (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica, 91, pp. 475-481.
6. Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J. D. and Belhadj, K. (2005) [18F]fluoro-2-deoxy--glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood, 106, pp. 1376-1381.
7. Hutchings, M., Mikhaeel, N. G., Fields, P. A., Nunan, T. and Timothy, A. R. (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol, 16, pp. 1160-1168.
8. Mikhaeel, N. G., Hutchings, M., Fields, P. A., O'Doherty, M. J. and Timothy, A. R. (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol
9. Romer, W., Hanauske, A. R., Ziegler, S., Thodtmann, R., Weber, W. and Fuchs, C. (1998) Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood, 91, pp. 4464-4471.
10. Kostakoglu, L., Coleman, M., Leonard, J. P., Kuji, P., Zoe, H. and Goldsmith, S. J. (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med, 43, pp. 1018-1027.
11. Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F. and Hansen, M. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol, 25, pp. 3746-3752.
12. Skinnider, B. F. and Mak, T. W. (2002) The role of cytokines in classical Hodgkin lymphoma. Blood, 99, pp. 4283-4297.
13. Lin, C., Itti, E., Haioun, C., Petegnief, Y., Luciani, A. and Dupuis, J. (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med, 48, pp. 1626-1632.
14. Zinzani, P. L., Tani, M., Fanti, S., Alinari, L., Musuraca, G. and Marchi, E. (2006) Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients. Ann Oncol, 17, pp. 1296-1300.
15. Hasenclever, D. and Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med, 339, pp. 1506-1514.
16. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U. and Hasenclever, D. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med, 348, pp. 2386-2395.
17. Federico, M., Luminari, S., Dell'Olio, M., Merli, F., Brugiatelli, M. and Stelitano, C. (2007) ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica, 92, p. 34.
18. Hasenclever, D. (2002) The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol, 13, pp. 75-78.
19. Gallamini, A., Viviani, S., Bonfante, V., Levis, A., Raimondo, F Di and Merli, F. (2007) Early interim FDG-PET during intensified BEACOPP therapy shows a lower predictive value than during conventional ABVD chemotherapy. Haematologica, 92, p. 71.
20. Avigdor, A., Bulvik, S., Dann, E. J., Levi, I., Perez-Avraham, G. and Shemtov, N. (2007) Combined ESCBEACOPP-ABVD therapy for advanced Hodgkin's lymphoma patients with high IPS score: An effective regimen and low positive predictive value of early FDG-PET/CT. Haematologica, 92, p. 66.
21. Kasamon, Y. L., Wahl, R. L. and Swinnen, L. J. (2004) FDG PET and high-dose therapy for aggressive lymphomas: Toward a risk-adapted strategy. Curr Opin Oncol, 16, pp. 100-105.
22. Dann, E. J., Bar-Shalom, R., Tamir, A., Haim, N., Ben-Schachar, N. and Avivi, I. (2007) Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood, 109, pp. 905-909.